Alnylam is the latest partner in the Medicines Manufacturing Innovation Centre’s third Grand Challenge project, which aims to revolutionise the manufacturing process for oligonucleotide therapies
The investment programme is expected to significantly reduce commercialisation lead times, costs and introduce more sustainable manufacturing processes
Marketed under the brand name DGJAJ, it helps in the faster recovery of hospitalised patients and reduces supplemental oxygen dependence
The drug has been granted permission by DCGI for emergency use as an adjunct therapy for Covid-19
2DG has been given emergency approval by the Drug Controller General of India (DCGI) for use on COVID-19 patients in the country
BALflu is approved by DCGI for emergency use for the treatment of COVID-19
The drug accumulates in the virus infected cells and prevents virus growth by stopping viral synthesis and energy production
Indian government is expecting pharmaceutical industry to fetch incremental sales worth Rs. 294,000 crore and exports up to Rs. 196,000 crore by FY 2027-28
ICICI Securities expects Hemmo to grow its revenue at a CAGR of 30.0% over FY21E-FY23E
This acquisition marks PPS’ foray into the development and manufacturing of peptide APIs
Subscribe To Our Newsletter & Stay Updated
